News & Opinionn

 

Are Statins Overprescribed? For Many, Their Risks May Outweigh Their Benefits

 

By Jonathan Block

December 5, 2018

Are Statins Overprescribed? For Many, Risks of the Drugs May Outweigh Their Benefits

A new study is arguing that statins may be overprescribed since in many people, the risks of the cholesterol-lowering drugs outweigh their benefits.

Current US guidelines recommend that statins be prescribed to those who have a 10% risk of having a heart attack within the next 10 years and who have one or more risks for cardiovascular disease (CVD), such as high cholesterol, high blood pressure and diabetes. With those guidelines, as many of 40% of older Americans should take a statin to curtail their risk of developing heart disease or having a cardiovascular event.

Statins, however, are considered a must for those that have experienced a heart attack or stroke, as clinical evidence is strong that they can prevent another one from occurring.

Researchers looked at data from more than 40 studies on four commonly prescribed statins: Lipitor (atorvastatin), Zocor (simvastatin) Pravachol (pravastatin) and Crestor (rosuvastatin). They used a computer model to analyze the benefits and risks of statins. Possible side effects included muscle weakness, kidney or liver dysfunction, diabetes, cataracts and headaches.

Results, published in the Annals of Internal Medicine, found that the harms of the drug outweigh the benefits until a patient’s risk is much higher than the 10% threshold cited in the US guidelines.

For example, a net benefit was not seen in men between 70 and 75 unless their 10-year CVD risk was at least 21%. Among men 40 to 44, the benefit was not greater than risk unless their risk was at least 14%.

Milo Puhan, MD, PhD, a senior author of the study with the University of Zurich, told NPR that as people age, the benefits of statins diminish compared to harm. He added that only 15% to 20% of older adults should be taking statins, much less than the 40% under the current guidelines.

Average: 3.5
Jonathan Block
Jonathan Block

Jonathan Block is MedShadow’s content editor. He has previously worked for Psychiatry Advisor, Modern Healthcare, Health Reform Week and The Pink Sheet.

 

Last updated: December 5, 2018